

Rome, 25/11/2025

Prot. n. 547/DG

BAMBINO GESÙ CHILDREN'S HOSPITAL THE GENERAL DIRECTOR

HAVING SEEN Legislative Decree No. 36 of 31 March 2023 and subsequent amendments (hereinafter the "Public Contracts Code"), as amended;

HAVING SEEN the Presidential Decree of 5 October 2010, no. 207, as currently in force, which regulates the execution and implementation of the Public Contracts Code;

HAVING SEEN the contracting decision no. 154 prot. no. 516/DG of 12/11/2025, the preamble of which is hereby deemed to be fully incorporated, by which the General Director of the Bambino Gesù Pediatric Hospital ("OPBG") authorized the initiation of the procedure through direct award pursuant to art. 50, paragraph 1, letter b), of Legislative Decree 36/2023 for the activation of analytical services necessary for the development of assays for the presence of replication-competent retroviruses in 2 Master Cell Banks and in their respective viral vectors for research activities at the Pharmaceutical Laboratory of the Bambino Gesù Pediatric Hospital, through financing with PNRR funds - NextGenerationEU, Mission 4 Component 2 from Research to Business, Investment 1.4, within the Research Program "Strengthening research structures and creation of "national R&D champions" on some Key Enabling Technologies", approved with Directorial Decree of the Ministry of University and Research no. 3138 of 16 December 2021, amended by Directorial Decree no. 3175 of 18 December 2021. The above-mentioned services are provided by BioReliance Ltd for an amount equal to Euro 35,125.00 (thirty-five thousand one hundred and twenty-five/00), plus VAT, where applicable, as reported in the Contracting Decision, simultaneously appointing Dr. Monica Gunetti as the Sole Project Manager, pursuant to Article 15 of the Public Contracts Code;

HAVING SEEN the transmission on 20/11/2025 by the OPBG to the economic operator BioReliance Ltd of the invitation letter with the related attachments,

indicating 18:00 on 04/12/2025 as the final deadline for participation in the tender procedure in question;

HAVING SEEN the response to the invitation letter sent by BioReliance Ltd acquired in the OPBG records on 21/11/2025, accompanied by all the required documentation digitally signed;

HAVING SEEN the evaluation document dated 24/11/2025 with which the proposed technical offer was examined;

HAVING SEEN the evaluation document dated 24/11/2025, with which the economic offer was assessed as appropriate for the amount of Euro 35,125.00 (thirty-five thousand one hundred and twenty-five/00), plus VAT, where applicable, as reported in the Contract Determination;

WHEREAS the OPBG has initiated the verification of the prescribed requirements in relation to BioReliance Ltd;

CONSIDERING that it is necessary to proceed with the awarding of the above-mentioned tender on the basis of the documents and documentation produced, necessary for the stipulation of the contract;

CONSIDERING that, as provided for by Article 17, paragraph 5 of the Public Contracts Code, the award becomes effective after positive verification of the possession of the required requirements, as well as the establishment of the definitive guarantee referred to in Article 8 of the Contract Specifications;

HAVING SEEN the CUP E83C22003170001 assigned by the Ministry of Health;


All of the above having been seen, considered and stated, which constitutes an integral part of this provision

ARRANGE

1. to award the tender procedure by direct award pursuant to art. 50, paragraph 1, letter a) to the company **BioReliance Ltd**, with registered office in Glasgow, Scotland, at Unit 5, Todd Campus, West of Scotland Science Park, G20 0XA, Tax Code 6805014990 / VAT number GB 845 3370 24. b), of Legislative Decree 36/2023 for the activation of analytical services necessary for the development of assays for the presence of replication-competent retroviruses in 2 Master Cell

- Banks and in their respective viral vectors for research activities at the Pharmaceutical Laboratory of the Bambino Gesù Pediatric Hospital, through financing with PNRR funds - NextGenerationEU, Mission 4 Component 2 from Research to Business, Investment 1.4, within the Research Programme "Strengthening research structures and creation of "national R&D champions" on some Key Enabling Technologies", approved with Directorial Decree of the Ministry of University and Research no. 3138 of 16 December 2021, amended by Directorial Decree no. 3175 of 18 December 2021. The above mentioned services are provided by BioReliance Ltd for an amount equal to Euro 35,125.00 (thirty-five thousand one hundred and twenty-five/00), plus VAT, where applicable, as reported in the Contracting Decision;
2. that the aforementioned award becomes effective only following the activation of the definitive guarantee constituted by BioReliance Ltd, pursuant to art. 117 of Legislative Decree 36/2023, in the forms provided for by art. 106 of Legislative Decree 36/2023, as provided for in art. 8 of the Specifications, within 10 days of the signing of this award decree;
 3. that the aforementioned award becomes effective only following the positive outcome of the checks required by the legislation in force on the participation requirements;
 4. which, following the checks foreseen in points 2 and 3, will be followed by the necessary formalisation of the contract;
 5. to advertise the award using the methods provided by law.

The General Director
Antonio Perno


1.12.2025